Search - tctmd.com

Displaying 1 - 8 of 8

Sort: Relevancy | Date

Presentation AHA 2024

Efficacy and safety of EdoxabaN in anticoagulant therapy after surgical Bioprosthetic vALVe replacement

Presenter: Chisato Izumi

November 17, 2024

Presentation CACI 2019

¿Qué papel juegan actualmente los nuevos anticoagulantes en la prevención del stroke?

Presenter: Nicolás Gonzalez

November 29, 2019

Presentation

CLOSE: Closure of PFO, Oral Anticoagulants, or Antiplatelet Therapy to Prevent Stroke Recurrence

May 24, 2017

Presentation

Time to Cost-Effectiveness After Stroke Reduction Strategies in A-fib: Warfarin vs Novel Oral Anticoagulants (NOACs) vs Left Atrial Appendage (LAA) Closure

Presenter: Vivek Y. Reddy

December 13, 2015

Presentation TCT 2014

Atrial Fibrillation: Stratifying Stroke Risk and Determining Anticoagulant Therapy

Presenter: Hilary Nierenberg, Julie Logan, Asma Hussaini

September 14, 2014

Presentation TCT 2012

Novel Anticoagulants for Stroke Prevention in Patients with Atrial Fibrillation

Presenter: Jonathan Halperin

October 25, 2012

Presentation

Meta-Analysis of Efficacy and Safety of New Oral Anticoagulants (Dabigatran, Rivaroxaban, Apixaban) vs. Warfarin in Patients with A-fib

Presenter: Corey S. Miller

May 03, 2012

Presentation

New Oral Anticoagulants for Stroke Prevention

Presenter: Nicole R. Gonzales

May 02, 2012

Advertisement

Efficacy and safety of EdoxabaN in anticoagulant therapy after surgical Bioprosthetic vALVe replacement

¿Qué papel juegan actualmente los nuevos anticoagulantes en la prevención del stroke?

CLOSE: Closure of PFO, Oral Anticoagulants, or Antiplatelet Therapy to Prevent Stroke Recurrence

Time to Cost-Effectiveness After Stroke Reduction Strategies in A-fib: Warfarin vs Novel Oral Anticoagulants (NOACs) vs Left Atrial Appendage (LAA) Closure

Atrial Fibrillation: Stratifying Stroke Risk and Determining Anticoagulant Therapy

Novel Anticoagulants for Stroke Prevention in Patients with Atrial Fibrillation

Meta-Analysis of Efficacy and Safety of New Oral Anticoagulants (Dabigatran, Rivaroxaban, Apixaban) vs. Warfarin in Patients with A-fib

New Oral Anticoagulants for Stroke Prevention

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content